Haemostatic agent

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex


The present invention relates to the field of medicine and veterinary medicine and can be used for rapid hemostatic effect in the provision of emergency medical care and self-help in emergency situations (armed conflicts, catastrophes, natural disasters), industrial, household trauma, etc.

Known hemostatic drug for the treatment of wounds of warm-blooded mammals (patent US No. 4822349, IPC A61F 13/02, A61L 15/18, publ. 18.04.1989 G.), in which the zeolite is prepared in the binder - clay, and is applied directly to the wound. But there is a strong exothermic effect, resulting in strong thermal burn tissues.

Also known hemostatic material (application US No. 20050074505, IPC 7 AC 33/06, publ. 07.04.2005). It is a composition consisting of binders based on clay and zeolite placed in a binder, wherein the zeolite has adjusted the calcium content is from 75% by weight. up to 83% by weight., which is produced by adding a calcium compound to the source zeolite, wherein calculaterate compound selected from the group consisting of calcium oxide, calcium sulphates and chlorides of calcium. This material has the following disadvantages: very high calcium concentration, significantly exceeding the best - 0,8-1,75 mmol/l (D. M. Tooth�the moat. Biochemistry of blood coagulation. - M.: Medicine. - 1978), which reduces the clotting. This solid composition, and if it enters an open wound of the oxides and chlorides of calcium possible chemical burns to tissues. The hardened mass traumatize the wound edges when removing it from the wound, and when the position of the injured area.

Also known selected as a prototype hemostatic drug (application 2007114557/15, publ. 17.04.2007) on the basis of zeolite, comprising a compound of calcium, according to the proposed solution contains as compounds of calcium ground calcium carbonate and boehmite nanoparticles and the polysaccharide and/or lignin in the following ratio of components, wt.%:

Nanoparticles of boehmite20-40
Ground calcium carbonate5-10
The polysaccharide and/or lignin10-20

This drug has the following disadvantages: there is no antiseptic effect when applied into the wound, the drug is time-consuming to manufacture, solid composition partially in contact with wound surface, there is a thermal eff�CT when applied to the wound, ground calcium carbonate (PR=3.8·10-9) is practically insoluble in water.

The technical task of the invention is the creation of the drug, quickly stopping the blood, ensuring full contact with the wound or enveloping her without causing pain. The drug must be possible the introduction of antiseptic and antinociceptive components to extend its medical action.

The challenge is the fact that in hemostatic drug containing polysaccharide, inputs of one or more water-soluble hemostatic agents (eg, calcium chloride), organic or inorganic acid, distilled water, with the following ratio of components, wt.%:

Hemostatic additive0.01 to 2%
Organic or inorganic acid0.5 to 6%
Distilled waterelse

When creating the drug was analyzed available literature data on the mechanism of thrombosis in the body. The process swertia�I blood is a cascade of enzymatic reactions, in which proenzymes (predecessors), transitioning to the active state, is able to activate other coagulation factors (human Physiology / ed Pokrovsky V. M., Korotko G. F. - M.: Medicine - 1997 - T1 - 448 p.). In the basis of blood coagulation is the conversion of the soluble plasma protein fibrinogen into the insoluble protein fibrin. Among the agents of the process are calcium ions and prothrombin. This plasma protein is produced in the liver, and its formation requires vitamin K. the Process cannot begin without another component - thromboplastin - protein-phospholipid fragment of the membranes of platelets, cells of the vascular wall, collapsing in bleeding. In the presence of calcium ions and thromboplastin and prothrombinase prothrombin is converted to thrombin, which converts the soluble protein fibrinogen into insoluble fibrin. Important role in the mechanism of cessation of bleeding platelets play. Until the vessels are damaged, platelets adhere to vessel walls, but in violation of their integrity or the appearance of abnormal roughness they settle on damaged surfaces, stick together with each other and release substances that stimulate blood clotting. This forms a blood clot, which is when growth turns into a clot.

It is necessary to clarify the ro�ü calcium ions.

1. Calcium ions are necessary for giving the native conformation of coagulation factors, after which the latter are able to participate in enzymatic reactions of hemostasis.

2. Calcium ions act as bridges between the protein components and cell membranes. These calcium bridges there is an initial orientation of coagulation factors on phospholipid matrix, and as a result the conformation of protein molecules open active centers.

In this hemostatic product feature matrix - a kind of analogue of the lipid bilayer membrane of blood cells and their fragments thromboplastin - performs chitosan. Chitosan is non-toxic biocompatible component, is able to dissolve in the biological environment. It acts as energy and plastic material during epithelization of the wound. During application of the drug after stop bleeding on a wound film is formed, enveloping the wound. It is breathable and transmits ultraviolet (additional disinfecting effect), does not require removal and replacement, promotes the flow of exudate from the wound.

The experiments in vitro and in vivo, during which the maximum effectiveness of the drug when the content of calcium ions from 0.01-1 wt. % and the polysaccharide is 0.5-20 wt. %. The content of organic�tion or inorganic acid should not exceed 5 wt. % to ensure the pH of the drug close to the pH value of the skin.

The ability to perform hemostatic drug in the form of films, gels, sponges or foam of different densities is achieved by introducing an additional crosslinking agent and foaming agent.

You can enhance the hemostatic properties of the drug by the introduction of antiseptic and antinociceptive dobavkok, providing additional bactericidal and analgesic effect.

The production of this drug is not harmful to the environment, production costs are low (simple non-energy-intensive technology, a large number of raw materials). This drug has no side effects, does not cause allergies and has healing and antiseptic effect.

The proposed hemostatic drug has the following effects:

1. Stimulates the regeneration of tissue in the wound area.

2. Calcium ions during their adsorption on polysaccharide accelerate the start of the process of thrombosis. Blood clots within 20-40 C.

3. The polysaccharide chitosan provides anti-inflammatory, antiviral effect and easy analgesic effect.

4. The drug provides a tight contact with the wound and gently wraps the wound.

5. For drugs having good adhesion to the tissues and congruence with wound surface

6. The drug does not cause allergic reactions.

7. The drug does not cause painful sensations.

8. No exothermic effect in contact with the wound.

9. Perhaps the introduction of antiseptic components for additional bactericidal effect.

10. Perhaps the introduction antinociceptive components for additional analgesic effect.

11. The drug is not toxic.

The technical result from the use of the invention is to accelerate the start of the process of clot formation and strengthening of regenerative capacity of tissues in the field of various etiologies due to the introduction in the drug-containing polysaccharide, water-soluble hemostatic products.

Below are examples of specific tests.

The test samples obtained hemostatic drug was conducted in the laboratory on experimental animals.

For experience took 10 nonlinear rats, 5 of them intact (normal) and 5 experienced. All animals were dissected skin flap left thigh about the size of 2×2 cm, exposing the femoral vein, and made a neat incision, after which the wounds of experimental animals was applied hemostatic drug composition No. 1-14. In intact rats the blood clot within 90-120 seconds, while subjects under the influence of the drug within 40 CE�und. Caused product film formed on the wounds. Further observation of the experimental animals showed that wounds treated with the drug, formation of epithelial cover was twice as fast and without infection.

The hemostatic compositions of the preparation:

Hemostatic drug containing 3-20 wt%. polysaccharide, where the polysaccharide represented by the chitosan and/or starch, 0.1 to 2 wt%. calcium chloride and 0.5-5% aqueous solution of succinic acid or hydrochloric acid - the rest.


Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula


The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

FIELD: medicine.

SUBSTANCE: antiproteolytic preparation Ambene in a dose of 50-250 mg is introduced intravenously by the stream infusion for at least three days every 3-4 hours in a combination with heparin. Heparin is introduced subcutaneously is a dose of 250 units 4 times a day.

EFFECT: effective treatment of endogenous intoxication syndrome caused by proteolysis by blocking fibrinolysis and enhancing the detoxifying and anti-inflammatory action of Ambene.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: what is described is a biodegradable haemostatic therapeutic agent for control of bleeding, which provides co-immobilising ε-aminocapronic acid 50 mg, lysozyme 5 mg in distilled water 6.5 l for 3 hours at room temperature for dialdehyde cellulose 1 g at a degree of oxidation 12%. The material is pressed out and dried to residual moisture no more than 10% in the air in darkness. After having dried, the material is milled in a fine mill to particles having a size of 20 to 50 mcm. A rate of control of bleeding is 102 seconds. A time of total resorption is 10 days.

EFFECT: agent provides a high degree of hydrolytic destruction and a good haemostatic activity.

4 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a biodegradable haemostatic therapeutic agent for bleeding. Using the prepared haemostatic agent according to the declared method provides a rate of control of bleeding making 45±2 seconds.

EFFECT: higher rate of control of bleeding.

4 cl, 2 tbl

FIELD: chemistry.

SUBSTANCE: agent further contains aluminium and/or magnesium oxides and satisfies the formula: CaO·(SiO2)m·(M)n·(H2O)k, where M is Al2O3 and/or MgO; m=0.5-3.0; n=0.01-0.05; k=0.2-1.2.

EFFECT: shorter time for onset of hemostasis and low exothermic effect during interaction with blood.

2 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hematology and oncology, and concerns correction of amegakaryocytic thrombocytopenia. That is ensured by introducing a platelet concentrate and performing autologous peripheral haemopoietic stem cell transplantation with performing a single subcutaneous injection of romiplostim 200-300 mcg on the day of the transplantation.

EFFECT: method provides reducing a risk of the haemorrhagic complications following the high-dose chemotherapy, ensured by the fast and effective platelet growth.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: agent contains chitosan salt 75-95 wt % of polydisperse powders of chitosan hydrochloride, hydrobromide, formate, acetate, succinate, citrate, glycolate or lactate and polyhexamethylene guanidine hydrochloride 4-20 wt %. The chitosan salt and polyhexamethylene guanidine hydrochloride are covalently cross-linked by a polyfunctional compound 1-5 wt % of glycidyl ethers. The chitosan salt is specified with an average particle size of 0.2÷2.0 mm, degree of chitosan deacetylation 0.75÷0.95, and molecular weight 10÷500 kDa. The above polyfunctional compound of glycidyl ethers is presented by a diglycidyl ether of butandiol, di- or triethylene glycol or propylene glycol, oligoethylene oxide, as well as triglycidyl ethers of glycerol or trimethylol propane.

EFFECT: method possesses high blood sorption capacity, rapid hemostasis time and high antimicrobial activity.

3 cl, 2 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention represents a hemostatic preparation containing a complex of aminocaproic acid and ferric iron stabilised with sodium chloride in the isotonic concentration. The invention aims at wound healing, small hemostasis at administering the first medical aid at the pre-hospital emergency evacuation.

EFFECT: what is provided is preparing the preparation very soluble in water and possessing high hemostatic activity, low costs and extended storage period.

FIELD: medicine.

SUBSTANCE: method for preparing a gel for wound and burn healing involving diluting chitosan in an organic acid, combining it with a biologically active substance and water; chitosan is diluted in citric or lactic acid; mussel hydrolysate is used as the biologically active substance; the hydrolysate is added to the chitosan solution before PEG 600 and calcium alhylose are added in the certain environment.

EFFECT: method enables preparing the new effective wound-healing agent.

2 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: pharmaceutical composition contains drug substances and a consistency-forming base. According to the invention, it contains anaesthetics as drug substances specified in a group: anaesthesine, lidocaine, promedol and antiseptic specified in a group of: ethacridine lactate, Furacilin, dioxidine, chlorhexidine, boric acid, 0.5% silver solution in the following ratio, g in 1 ml of the mixture: anaesthetics 0.00001-0.5; antiseptics 0.00001-0.5; consistency-forming base - the rest. Besides, it contains lysozyme in an amount of 0.1-0.3 g per 1 ml of the mixture, alpha-lipoic acid as an antioxidant in an amount of 0.00001-0.5 g per 1 ml of the mixture, regenerants specified in a group of: pantothenic acid, calcium pantotenate, beta-carotene, coenzyme Q, sodium deoxyribonucleate, inosine, vitamins A, D, E, K in an amount of 0.00001-0.5 g per 1 ml of the mixture, anabolics specified in a group of: methyluracil, riboxinum, potassium orotate, orotic acid, L-carnitine in an amount of 0.00001-0.5 g per 1 ml of the mixture, glycyrrhizic acid and/or its salts in an amount of 0.00001-0.5 g per 1 ml of the mixture, recombinant interferon specified in a group of: recombinant interferon-alpha, recombinant interferon-beta, recombinant interferon-gamma in an amount of 100-1,000,000 International units, glucocorticoids specified in a group of: hydrocortisone, prenisolone, polcortolone in an amount of 0.00001-0.5 g per 1 ml of the mixture. The consistency-forming base contains the components specified in a group: hypromellose, sodium alginate, acetyl phthalyl cellulose, macrogol, polyvinylpyrrolidone.

EFFECT: improving the properties of the composition.

9 cl, 11 ex

FIELD: medicine.

SUBSTANCE: what is described is a bioactive wound coating of a hydrogel nanocomposite, which contains antimicrobial and antioxidant ingredients: silver-modified montmorillonite and fullerenol used to optimise the clinical course of the wound process, to prevent and suppress a wound infection. The wound coating can be used to treat gun-shot injuries, severe mechanical injuries, infected and uninfected wounds, including septic and persistent, granulating wounds following deep thermal, chemical and radioactive burns, in the combined therapy of trophic ulcers and bed sores at hospital, in the outpatient setting and in the field. The wound coating is elastic, not fragmented in dressing that facilitates wound care. A high sorption ability of the wound coating matrix, including of coarse-molecular ingredients of the wound effluent, provides the fast elimination of the wound bed. Using the hydrogel, i.e. possessing high degree of hydration, the wound coating meets the modern wound management in the humid medium.

EFFECT: optimum conditions for the early activation of the repair processes.

5 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: wound surface is treated with 3.0-1.5% hydrogen peroxide; then keeping the wound wet, Ichthyosin dressing prepared by streptocide powder 0.5-2.5g and Ichthyol ointment 5.0-10.0g dissolved in castor oil 94.5-87.5ml is applied. The agent is applied once a day; the therapeutic course makes 16 days. That is combined with performing an integrated treatment.

EFFECT: invention provides both the antibacterial and anti-infectious, and local anti-inflammatory, local anaesthetic, wound-healing effects, improves the blood supply, stimulates the epidermis regeneration, intensifies the keratosis processes that enables accelerating the wound cleansing from the purulonecrosis process, and a length of preparation for aurografting.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions concerns a method for preparing Sostakovsky balsam containing mixing vinyl butyl ether and butyl alcohol, heating a reaction mass while stirring continuously, feeding a catalyst after achieving the required temperature, decontaminating the prepared polymer, pouring out the polymer heated to 50-70°C into a container through a multilayer filter; the above group also concerns the therapeutic agent possessing the wound-healing, bacteriostatic and analgesic properties and prepared by the above method.

EFFECT: higher yield and purity of the produced preparation as compared to the similar methods with preserving the pharmacological properties inherent to the given preparation.

5 cl, 1 ex

FIELD: medicine.

SUBSTANCE: treating trophic ulcers is ensured by using autoserum prepared of blood 20.0-25.0 ml; centrifuging and separating it from a protein-thrombocyte clot are followed by edge chipping under a wound bed, while the protein-thrombocyte clot is used to be laid on the wound directly. The above procedures are repeated up to 20 times every two days.

EFFECT: invention enables providing fast wound healing with the adequate recovery of the dermal skin layer by using the high-biocompatibility material containing the ingredients creating the optimum medium for the wound regeneration.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a therapeutic agent used for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by a multifunction kinase inhibitor (MKI) therapy and containing a therapeutically effective amount of allopurinol or its pharmaceutically acceptable salt.

EFFECT: invention provides extending the range of products for treating or preventing palmar-plantar erythrodysesthesia syndrome (PPES) induced by the multifunction kinase inhibitor (MKI) therapy.

21 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a preparation possessing anti-inflammatory, analgesic and wound-healing action. The preparation possessing the anti-inflammatory, analgesic and wound-healing action represents a mixture of an alcoholate of lilac blossom and plantain leaves with honey and extracted juice of unpeeled pomegranate.

EFFECT: preparation possesses the pronounced anti-inflammatory, analgesic and wound-healing action.

6 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for treating an individual having a slowly healing or chronic wound. That is ensured by administering a composition containing therapeutically effective amounts of an anti-connexin43 agent, and a protein or a peptide effective for stimulating or improving the wound healing into the individual in need thereof. What is also presented is using the therapeutically effective amount of a first wound-healing compound and a second wound-healing compound, wherein the above first wound-healing compound represents the anti-connexin43 agent, while the above second wound-healing compound is specified in a group consisting of beta-adrenergic antagonists, interleukin-1 receptor antagonists, free radical scavengers, anti-inflammatory and antimicrobial agents, opioids, connexin phosphorylation agents.

EFFECT: group of inventions provides higher rate and/or quality of wound healing by means of using the above combination of the therapeutic agents when it is possible to reduce the dose and rate of administration.

46 cl, 19 dwg, 8 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, specifically to drug preparations of erythropoietin (EPO) for the regeneration of injured tissues, and can be used in medicine. EPO is used for producing a drug preparation for a patient's structural neogenesis. If a wound represents a burn injury, EPO is applied locally on the burn wound by a skin graft to be applied on the above wound treated by EPO. Skin diseases require the local introduction of EPO into the blood coagulate of a wound bed which is mechanically pre-treated before EPO is applied, or EPO is introduced as a part of a slow-soluble hydrogel of fibrin, polymer or alginate by the local application of the above hydrogel.

EFFECT: invention enables accelerating the granulation tissue formation accompanying the patient's structural neogenesis and ensuring the skin burn healing with no scarring.

11 ex

FIELD: chemistry.

SUBSTANCE: method includes milling glauconite with the content of rock from 20 to 95%, selection of a fraction of 1.0-10 mcm, preparation of a 40-80% suspension of glauconite in water. The obtained suspension is processed by ultrasound with a frequency of 15-25 kHz for 2-5 minutes. As a result obtained is a glauconite-based enterosorbent, which represents a 40-80% suspension of the glauconite 1.0-10 mcm fraction in water.

EFFECT: obtaining the glauconite-based enetrosorbent, which has the increased sorption ability in the form of a stable water suspension of glauconite.

2 cl, 2 tbl, 2 ex